CPSF7

Summary

CPSF7 (cleavage and polyadenylation specific factor 7, HGNC:30098) is a protein-coding gene on chromosome 11q12.2, encoding Cleavage and polyadenylation specificity factor subunit 7 (Q8N684). Component of the cleavage factor Im (CFIm) complex that functions as an activator of the pre-mRNA 3’-end cleavage and polyadenylation processing required for the maturation of pre-mRNA into functional mRNAs.

Cleavage factor Im (CFIm) is one of six factors necessary for correct cleavage and polyadenylation of pre-mRNAs. CFIm is composed of three different subunits of 25, 59, and 68 kDa, and it functions as a heterotetramer, with a dimer of the 25 kDa subunit binding to two of the 59 or 68 kDa subunits. The protein encoded by this gene represents the 59 kDa subunit, which can interact with the splicing factor U2 snRNP Auxiliary Factor (U2AF) 65 to link the splicing and polyadenylation complexes.

Source: NCBI Gene 79869 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 74 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001142565

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30098
Approved symbol	CPSF7
Name	cleavage and polyadenylation specific factor 7
Location	11q12.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ12529, CFIM59
Ensembl gene	ENSG00000149532
Ensembl biotype	protein_coding
OMIM	621247
Entrez	79869

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 22 protein_coding, 6 nonsense_mediated_decay, 4 retained_intron, 3 protein_coding_CDS_not_defined

ENST00000340437, ENST00000394888, ENST00000413184, ENST00000413232, ENST00000439958, ENST00000448745, ENST00000449811, ENST00000450000, ENST00000463244, ENST00000474684, ENST00000477890, ENST00000489728, ENST00000494016, ENST00000535222, ENST00000536145, ENST00000536548, ENST00000537162, ENST00000537641, ENST00000539952, ENST00000541963, ENST00000543545, ENST00000544585, ENST00000544669, ENST00000544990, ENST00000545934, ENST00000626926, ENST00000859445, ENST00000859446, ENST00000859447, ENST00000859448, ENST00000859449, ENST00000925919, ENST00000925920, ENST00000925921, ENST00000940949

RefSeq mRNA: 3 — MANE Select: NM_001142565 NM_001136040, NM_001142565, NM_024811

CCDS: CCDS44619, CCDS44620, CCDS8006

Canonical transcript exons

ENST00000439958 — 10 exons

Exon	Start	End
ENSE00001119031	61410938	61411105
ENSE00001119032	61415666	61415784
ENSE00001234175	61416105	61416519
ENSE00001834115	61429914	61429975
ENSE00001870107	61402729	61404704
ENSE00003508130	61420470	61420573
ENSE00003515479	61429182	61429290
ENSE00003561594	61411769	61411937
ENSE00003580208	61421390	61421608
ENSE00003628839	61419949	61420094

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 97.64.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.2825 / max 201.9018, expressed in 1817 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119995	29.3471	1816
119994	1.9047	1118
119992	0.4692	277
119996	0.4312	226
119993	0.1304	44

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	97.64	gold quality
adenohypophysis	UBERON:0002196	97.64	gold quality
pituitary gland	UBERON:0000007	97.58	gold quality
right lobe of thyroid gland	UBERON:0001119	97.08	gold quality
left lobe of thyroid gland	UBERON:0001120	96.96	gold quality
body of uterus	UBERON:0009853	96.91	gold quality
left ovary	UBERON:0002119	96.61	gold quality
thyroid gland	UBERON:0002046	96.56	gold quality
endocervix	UBERON:0000458	96.47	gold quality
right ovary	UBERON:0002118	96.38	gold quality
mucosa of stomach	UBERON:0001199	96.33	gold quality
ventricular zone	UBERON:0003053	96.33	gold quality
right coronary artery	UBERON:0001625	96.25	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.20	gold quality
metanephros cortex	UBERON:0010533	96.19	gold quality
popliteal artery	UBERON:0002250	96.18	gold quality
tibial artery	UBERON:0007610	96.17	gold quality
body of pancreas	UBERON:0001150	96.05	gold quality
left uterine tube	UBERON:0001303	96.05	gold quality
body of stomach	UBERON:0001161	96.03	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.97	gold quality
ganglionic eminence	UBERON:0004023	95.95	gold quality
lower esophagus	UBERON:0013473	95.95	gold quality
small intestine Peyer’s patch	UBERON:0003454	95.89	gold quality
descending thoracic aorta	UBERON:0002345	95.86	gold quality
aorta	UBERON:0000947	95.84	gold quality
right adrenal gland	UBERON:0001233	95.79	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.78	gold quality
ectocervix	UBERON:0012249	95.76	gold quality
granulocyte	CL:0000094	95.73	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

151 targeting CPSF7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798

Literature-anchored findings (GeneRIF, showing 3)

• Data provide evidence that CFIm exists as a heterotetramer of 25-kD, 59-kD and 68-kD subunits of CFIm: CFIm25, CFIm59 and CFIm68. (PMID:20695905)
• The authors demonstrate that CFIm functions as an enhancer-dependent activator of mRNA 3’ processing. CFIm regulates global alternative polyadenylation by specifically binding and activating enhancer-containing poly(A) sites. (PMID:29276085)
• CPSF7 promoted WWP2-FL due to the presence of PTEN ubiquitination sites in this longer transcript and regulates liver cancer growth by targeting WWP2-FL that in turn regulates AKT activation in a PTEN-dependent manner. (PMID:31837982)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cpsf7	ENSMUSG00000034820
rattus_norvegicus	Cpsf7	ENSRNOG00000020668
drosophila_melanogaster	Cpsf6	FBGN0035872
caenorhabditis_elegans		WBGENE00008362

Paralogs (1): CPSF6 (ENSG00000111605)

Protein

Protein identifiers

Cleavage and polyadenylation specificity factor subunit 7 — Q8N684 (reviewed: Q8N684)

Alternative names: Cleavage and polyadenylation specificity factor 59 kDa subunit, Cleavage factor Im complex 59 kDa subunit, Pre-mRNA cleavage factor Im 59 kDa subunit

All UniProt accessions (14): Q8N684, C9J286, C9J323, C9JM38, F5GXA3, F5H047, F5H1W4, F5H2K8, F5H5B7, F5H669, F5H6A8, F5H6M0, F5H6P5, J3QT54

UniProt curated annotations — full annotation on UniProt →

Function. Component of the cleavage factor Im (CFIm) complex that functions as an activator of the pre-mRNA 3’-end cleavage and polyadenylation processing required for the maturation of pre-mRNA into functional mRNAs. CFIm contributes to the recruitment of multiprotein complexes on specific sequences on the pre-mRNA 3’-end, so called cleavage and polyadenylation signals (pA signals). Most pre-mRNAs contain multiple pA signals, resulting in alternative cleavage and polyadenylation (APA) producing mRNAs with variable 3’-end formation. The CFIm complex acts as a key regulator of cleavage and polyadenylation site choice during APA through its binding to 5’-UGUA-3’ elements localized in the 3’-untranslated region (UTR) for a huge number of pre-mRNAs. CPSF7 activates directly the mRNA 3’-processing machinery. Binds to pA signals in RNA substrates.

Subunit / interactions. Component of the cleavage factor Im (CFIm) complex which is a heterotetramer composed of two subunits of NUDT21/CPSF5 and two subunits of CPSF6 or CPSF7 or a heterodimer of CPSF6 and CPSF7 (PubMed:20695905, PubMed:23187700, PubMed:8626397, Ref.22). The cleavage factor Im (CFIm) complex associates with the CPSF and CSTF complexes to promote the assembly of the core mRNA 3’-processing machinery. Interacts with NUDT21/CPSF5. Interacts (via Arg/Ser-rich domain) with FIP1L1 (preferentially via unphosphorylated form and Arg/Glu/Asp-rich region); this interaction mediates, at least in part, the interaction between the CFIm and CPSF complexes and may be inhibited by CPSF7 hyper-phosphorylation.

Subcellular location. Nucleus. Cytoplasm.

Post-translational modifications. Phosphorylated. Asymmetrically dimethylated on arginine residues by PRMT1.

Domain organisation. Contains an Arg/Ser-rich domain composed of arginine-serine dipeptide repeats within the C-terminal region that is necessary and sufficient for activating mRNA 3’-processing.

Similarity. Belongs to the RRM CPSF6/7 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8N684-1	1	yes
Q8N684-2	2
Q8N684-3	3

RefSeq proteins (3): NP_001129512, NP_001136037, NP_079087 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034772	CPSF6/7	Family
IPR034773	CPSF7_RRM	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR057951	CPSF6/7_RSLD_N	Domain

Pfam: PF00076, PF25524

UniProt features (28 total): modified residue 4, region of interest 4, strand 4, compositionally biased region 4, sequence conflict 3, helix 3, splice variant 2, chain 1, domain 1, cross-link 1, turn 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3N9U	X-RAY DIFFRACTION	1.92

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N684-F1	65.55	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 203, 205, 413, 423, 354

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-72187	mRNA 3’-end processing
R-HSA-73856	RNA Polymerase II Transcription Termination
R-HSA-77595	Processing of Intronless Pre-mRNAs
R-HSA-9013422	RHOBTB1 GTPase cycle
R-HSA-9770562	mRNA Polyadenylation
R-HSA-9918481	Dengue Virus-Host Interactions
R-HSA-72203	Processing of Capped Intron-Containing Pre-mRNA

MSigDB gene sets: 197 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GCANCTGNY_MYOD_Q6, MAZ_Q6, SP1_Q2_01, CREB_Q4, GOBP_PROTEIN_HETEROTETRAMERIZATION, REACTOME_MRNA_3_END_PROCESSING, REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA, GATA1_01, GOBP_MRNA_3_END_PROCESSING, ACATTCC_MIR1_MIR206, TGANTCA_AP1_C, IK2_01, NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON, NRF2_01

GO Biological Process (6): mRNA 3’-end processing (GO:0031124), protein tetramerization (GO:0051262), protein heterotetramerization (GO:0051290), mRNA alternative polyadenylation (GO:0110104), co-transcriptional mRNA 3’-end processing, cleavage and polyadenylation pathway (GO:0180010), mRNA processing (GO:0006397)

GO Molecular Function (4): RNA binding (GO:0003723), mRNA binding (GO:0003729), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mRNA cleavage and polyadenylation specificity factor complex (GO:0005847), mRNA cleavage factor complex (GO:0005849), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Processing of Capped Intron-Containing Pre-mRNA	1
RNA Polymerase II Transcription	1
Processing of Capped Intronless Pre-mRNA	1
RHOBTB GTPase Cycle	1
mRNA 3’-end processing	1
Dengue Virus Infection	1
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
mRNA 3’-end processing	2
binding	2
mRNA processing	1
RNA 3’-end processing	1
protein complex oligomerization	1
protein tetramerization	1
protein heterooligomerization	1
co-transcriptional RNA 3’-end processing, cleavage and polyadenylation pathway	1
RNA processing	1
mRNA metabolic process	1
nucleic acid binding	1
RNA binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
mRNA cleavage factor complex	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1830 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CPSF7	NUDT21	O43809	998
CPSF7	U2AF2	P26368	939
CPSF7	CPSF1	Q10570	894
CPSF7	CPSF2	Q9P2I0	833
CPSF7	CSTF2	P33240	810
CPSF7	CSTF1	Q05048	804
CPSF7	CPSF4	O95639	796
CPSF7	CSTF3	Q12996	796
CPSF7	CPSF3	Q9UKF6	788
CPSF7	WDR33	Q9C0J8	788
CPSF7	CPSF6	Q16630	763
CPSF7	SYMPK	Q92797	757
CPSF7	PCF11	O94913	743
CPSF7	FIP1L1	Q6UN15	643
CPSF7	PTBP1	P26599	541

IntAct

172 interactions, top by confidence:

A	B	Type	Score
EMC2	EMC8	psi-mi:“MI:0914”(association)	0.940
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
CPSF6	NUDT21	psi-mi:“MI:0914”(association)	0.890
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
NUDT21	CPSF7	psi-mi:“MI:0915”(physical association)	0.740
CPSF7	NUDT21	psi-mi:“MI:0915”(physical association)	0.740
CPSF7	NCK2	psi-mi:“MI:0915”(physical association)	0.670
NCK2	CPSF7	psi-mi:“MI:0915”(physical association)	0.670
QPRT	PIK3C2A	psi-mi:“MI:0914”(association)	0.640
CPSF7	U2AF2	psi-mi:“MI:0915”(physical association)	0.620
CLK2	CPSF7	psi-mi:“MI:0915”(physical association)	0.560
SMAD3	CPSF7	psi-mi:“MI:0915”(physical association)	0.560
RUNX1T1	CPSF7	psi-mi:“MI:0915”(physical association)	0.560
CPSF7	TLE5	psi-mi:“MI:0915”(physical association)	0.560
CPSF7	SEC23B	psi-mi:“MI:0915”(physical association)	0.560
CPSF7	EPM2AIP1	psi-mi:“MI:0915”(physical association)	0.560
CPSF7	SNRNP25	psi-mi:“MI:0915”(physical association)	0.560
CPSF7	ARMC7	psi-mi:“MI:0915”(physical association)	0.560
CPSF7	SMAD3	psi-mi:“MI:0915”(physical association)	0.560
TLE5	CPSF7	psi-mi:“MI:0915”(physical association)	0.560
SEC23B	CPSF7	psi-mi:“MI:0915”(physical association)	0.560
EPM2AIP1	CPSF7	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (452): CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Two-hybrid), CPSF7 (Affinity Capture-RNA), CPSF7 (Affinity Capture-RNA), CPSF7 (Affinity Capture-RNA), CPSF7 (Affinity Capture-RNA), CPSF7 (Affinity Capture-MS)

ESM2 similar proteins: A0A1N7SYS3, A1A619, A3LP48, A9ULX8, B0BN56, D4A2Y9, F1NVK6, F6UF99, O04326, P40508, P82908, P82925, P92204, Q02854, Q04935, Q0P5B1, Q1LVV0, Q28GQ3, Q28HF6, Q28X44, Q2UDY8, Q3SYY7, Q3V0J1, Q56VL3, Q5I030, Q5R891, Q5XI29, Q61733, Q659C4, Q66IE4, Q68EU0, Q6AZH0, Q6BI17, Q6CHT7, Q6CJX5, Q6DFB7, Q6DFJ8, Q6NYD7, Q6PFM4, Q75D23

Diamond homologs: A0A0D1C8Z4, Q0P5D2, Q16630, Q5NVH8, Q5XI29, Q5ZL34, Q6DDW4, Q6NVF9, Q6NWC6, Q8BTV2, Q8N684, Q9VSH4, P10979, Q99070, Q03251

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CPSF7	“form complex”	“CFI complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 168 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA 3’-end processing	7	12.2×	2e-04
mRNA Splicing - Minor Pathway	6	11.9×	8e-04
mRNA Splicing	12	11.7×	5e-08
mRNA Polyadenylation	14	10.9×	1e-08
Processing of Capped Intron-Containing Pre-mRNA	14	10.2×	2e-08
RNA Polymerase II Transcription Termination	5	9.7×	9e-03
mRNA Splicing - Major Pathway	19	9.2×	1e-10
Dengue Virus-Host Interactions	17	6.9×	5e-08

GO biological processes:

GO term	Partners	Fold	FDR
mRNA transport	7	12.6×	3e-04
mRNA splicing, via spliceosome	20	12.6×	2e-13
positive regulation of transcription elongation by RNA polymerase II	6	12.4×	2e-03
negative regulation of translation	6	8.1×	9e-03
RNA splicing	12	7.2×	5e-05
mRNA processing	12	6.5×	1e-04
chromatin remodeling	10	5.0×	4e-03
transcription by RNA polymerase II	10	4.8×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	56
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2193 predictions. Top by Δscore:

Variant	Effect	Δscore
11:61411765:TCACC:T	donor_loss	1.0000
11:61411767:A:AT	donor_loss	1.0000
11:61411934:TCCC:T	acceptor_gain	1.0000
11:61411935:CCC:C	acceptor_gain	1.0000
11:61411935:CCCC:C	acceptor_gain	1.0000
11:61411936:CC:C	acceptor_gain	1.0000
11:61411936:CCC:C	acceptor_gain	1.0000
11:61411937:CC:C	acceptor_gain	1.0000
11:61411938:C:CA	acceptor_loss	1.0000
11:61411938:C:CC	acceptor_gain	1.0000
11:61411941:A:C	acceptor_gain	1.0000
11:61411948:A:C	acceptor_gain	1.0000
11:61415661:GTTA:G	donor_loss	1.0000
11:61415662:TTA:T	donor_loss	1.0000
11:61415663:TACCT:T	donor_loss	1.0000
11:61415664:A:T	donor_loss	1.0000
11:61415780:CTCGG:C	acceptor_gain	1.0000
11:61415781:TCGGC:T	acceptor_loss	1.0000
11:61415782:CGG:C	acceptor_gain	1.0000
11:61415783:GGC:G	acceptor_loss	1.0000
11:61415785:C:CC	acceptor_gain	1.0000
11:61415785:CTGTA:C	acceptor_loss	1.0000
11:61416422:AT:A	donor_gain	1.0000
11:61419920:ACCC:A	donor_gain	1.0000
11:61419921:CCCC:C	donor_gain	1.0000
11:61419947:A:AC	donor_gain	1.0000
11:61419948:C:CA	donor_gain	1.0000
11:61419948:CGTTT:C	donor_gain	1.0000
11:61420090:CATAC:C	acceptor_gain	1.0000
11:61420091:ATAC:A	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000016494 (11:61417041 A>C), RS1000033246 (11:61409876 G>A), RS1000040511 (11:61425301 C>A,T), RS1000099610 (11:61429038 A>T), RS1000114920 (11:61429657 C>A), RS1000170803 (11:61410113 T>C), RS1000280832 (11:61403145 A>G), RS1000326827 (11:61416716 A>C,G), RS1000700421 (11:61427894 G>A), RS1000743456 (11:61428119 T>C), RS1000777494 (11:61403403 A>G), RS1000852980 (11:61422184 C>T), RS1000994493 (11:61422569 G>A), RS1001065655 (11:61408704 G>A), RS1001200730 (11:61428723 G>A)

Disease associations

OMIM: gene MIM:621247 | disease phenotypes: MIM:213300

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), Joubert syndrome (MONDO:0018772)

Orphanet (2): Familial prostate cancer (Orphanet:1331), Isolated Joubert syndrome (Orphanet:475)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724758 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.78	Kd	1648	nM	CHEMBL5653589
5.78	ED50	1648	nM	CHEMBL5653589
5.01	IC50	9730	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 8 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148136: Binding affinity to human CPSF7 incubated for 45 mins by Kinobead based pull down assay	kd	1.6478	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179078: Inhibition of FLJ12529 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	9.7300	uM

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
sodium arsenite	increases abundance, increases expression, increases activity	2
Cadmium Chloride	decreases expression, increases abundance	2
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
sodium arsenate	decreases expression	1
coumarin	increases phosphorylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
LDN 193189	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	increases abundance, increases expression	1
Atrazine	increases expression	1
Vehicle Emissions	affects expression, increases abundance	1
Cadmium	decreases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Carbamazepine	affects expression	1
Gallic Acid	increases expression	1
Ivermectin	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Ribonucleotides	affects binding	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Particulate Matter	affects expression, increases abundance	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651178	Binding	Binding affinity to human CPSF7 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2V5	Abcam HEK293T CPSF7 KO	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer